Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) on November 5, 2024, covering events occurring on November 1, 2024. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
Departure of Joseph Truluck (Former CFO)
- Effective Date: November 1, 2024.
- Transition Period: Mr. Truluck served as CFO until November 15, 2024, and thereafter as a consultant.
- Compensation Terms:
- Nov 1, 2024 – Dec 31, 2024: 100% of current base salary.
- Jan 1, 2025 – Mar 31, 2025: 50% of current base salary as a consultant.
- After Mar 31, 2025: $350 per hour on an as-needed basis.
- Conditions: Agreement includes a general release of claims and a non-disparagement clause.
Appointment of Vinay Shah (New CFO)
- Effective Date: November 16, 2024.
- Background: Over 20 years of experience in medical device and biopharmaceutical finance, including prior CFO roles at Virpax Pharmaceuticals, Aravive, and Pacira Pharmaceuticals.
- Compensation Terms:
- Base Salary: $315,000 annually.
- Bonus: Discretionary bonus up to 30% of base salary.
- Equity: Eligible for a grant of stock options for 40,000 shares (terms to be determined by the Board).
- Severance: 6 months for "without cause" termination; 12 months for "without cause" termination following a change of control.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, operational outlook, or specific risk factors beyond the standard disclosure that the summary of agreements is subject to the full text of the attached exhibits. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price for the 40,000 stock options granted to Mr. Shah, as these terms are to be determined by the Board.
- Review the full text of the Separation Agreement (Exhibit 10.1) to confirm the specific base salary amount used to calculate Mr. Truluck's severance.
- Monitor the transition period between November 1 and November 16, 2024, to ensure continuity of financial reporting and operations.
- Confirm the availability of shares in the 2017 Equity Incentive Plan for Mr. Shah's option grant.